Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr-Jun;104(2):368504211016936.
doi: 10.1177/00368504211016936.

Publications and retracted articles of COVID-19 pharmacotherapy-related research: A systematic review

Ayman El-Menyar  1   2 , Ahammed Mekkodathil  2 , Mohammad Asim  2 , Rafael Consunji  3 , Sandro Rizoli  4 , Ahmed Abdel-Aziz Bahey  4 , Hassan Al-Thani  4
Affiliations

Publications and retracted articles of COVID-19 pharmacotherapy-related research: A systematic review

Ayman El-Menyar et al. Sci Prog. 2021 Apr-Jun.

Abstract

The current COVID-19 pandemic situation has stimulated an unplanned clinical research paradigm which is evident from the surge of clinical trial registrations and the increasing number of COVID-related publications. We aimed to explore the standards for research conduction, publications and retraction of articles related to COVID-19 pharmacotherapy research during the pandemic. We analysed data from the contemporary literatures on studies reporting pharmacological agents for COVID-19 using MEDLINE, PubMed, WHO database and Google Scholar between January 01, 2020 and March 20, 2021. The initial search revealed a total of 61,801 articles. Based on the inclusion criteria, a total of 124 studies related to various pharmacological agents were included in the final analysis. Most of the studies were reported from the United States (n = 30, 24%). Of the 124 studies, 50 (40%) were randomized controlled trials (RCTs). Immunomodulatory drugs-related (n = 17, 34%) and COVID-19 vaccine-related studies (n = 14, 28%) were the main topics in the relevant RCTs. The median days for dissemination of findings in journals were 114 days (IQR 61-189). A comparative analysis revealed that RCTs were disseminated earlier (median 79 days; IQR 52-131) when compared to observational studies (median = 144 days; IQR 69-206) (p = 0.003). Six papers were retracted from high impact journals; in which the average period till publication was 33 days. Retraction of papers occurred within 10-48 days. Expedited reviews, research approval and early publications of COVID-19 related pharmaceutical studies could have an impact on the quality of publications. However, the huge number of publications in short time creates confusion for readers during the early phases of the pandemic. Retraction of papers is alarming but ensures research integrity and correctness of scientific information. These abbreviated processes could affect patient care and public awareness. It is imperative to follow rapid but rigours ethical standards for research approval and peer-review process for publications during health pandemics.

Keywords: COVID-19 pandemic; pharmaceutical studies; publications; research ethics; retraction.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Flow diagram of study selection process.
Figure 2.
Figure 2.
Ethics standards during public health emergencies.
See this image and copyright information in PMC

References

    1. WHO status report: Coronavirus disease (COVID-19) weekly epidemiological update, https://www.who.int/publications/m/item/weekly-epidemiological-update-on... (2021, accessed 8 April 2021).
    1. Palayew A, Norgaard O, Safreed-Harmon K, et al. Pandemic publishing poses a new COVID-19 challenge. Nat Hum Behav 2020; 4: 666–669. - PubMed
    1. World Health Organization. Ethical standards for research during public health emergencies: distilling existing guidance to support COVID-19 R&D. Geneva, Switzerland: WHO, https://apps.who.int/iris/handle/10665/331507 (2020, accessed 20 March 2021).
    1. Huang M, Tang T, Pang P, et al. Treating COVID-19 with chloroquine. J Mol Cell Biol 2020; 12(4): 322–325. - PMC - PubMed
    1. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382(19): 1787–1799. - PMC - PubMed

Publication types

Substances

LinkOut - more resources